Cormorant Asset Management Llc decreased Bluebird Bio Inc (BLUE) stake by 41.82% reported in 2017Q4 SEC filing. Cormorant Asset Management Llc sold 57,500 shares as Bluebird Bio Inc (BLUE)’s stock declined 2.42%. The Cormorant Asset Management Llc holds 80,000 shares with $14.25 million value, down from 137,500 last quarter. Bluebird Bio Inc now has $8.94B valuation. The stock increased 2.18% or $3.8 during the last trading session, reaching $178.4. About 583,049 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 86.28% since May 17, 2017 and is uptrending. It has outperformed by 74.73% the S&P500.
Reilly Financial Advisors Llc decreased Aetna Inc New (AET) stake by 11.47% reported in 2017Q4 SEC filing. Reilly Financial Advisors Llc sold 8,277 shares as Aetna Inc New (AET)’s stock declined 6.45%. The Reilly Financial Advisors Llc holds 63,879 shares with $11.52 million value, down from 72,156 last quarter. Aetna Inc New now has $58.05B valuation. The stock increased 0.21% or $0.37 during the last trading session, reaching $177.47. About 1.46 million shares traded. Aetna Inc. (NYSE:AET) has risen 33.34% since May 17, 2017 and is uptrending. It has outperformed by 21.79% the S&P500.
Analysts await Aetna Inc. (NYSE:AET) to report earnings on August, 2. They expect $3.12 EPS, down 8.77% or $0.30 from last year’s $3.42 per share. AET’s profit will be $1.02B for 14.22 P/E if the $3.12 EPS becomes a reality. After $3.19 actual EPS reported by Aetna Inc. for the previous quarter, Wall Street now forecasts -2.19% negative EPS growth.
Among 24 analysts covering Aetna (NYSE:AET), 12 have Buy rating, 0 Sell and 12 Hold. Therefore 50% are positive. Aetna had 75 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Monday, August 7 with “Hold”. Jefferies maintained Aetna Inc. (NYSE:AET) on Tuesday, February 2 with “Hold” rating. Cantor Fitzgerald maintained Aetna Inc. (NYSE:AET) on Tuesday, January 30 with “Hold” rating. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, August 3 report. Jefferies maintained the stock with “Hold” rating in Wednesday, June 7 report. Citigroup downgraded it to “Hold” rating and $212.0 target in Wednesday, January 31 report. The company was maintained on Monday, October 23 by Cowen & Co. On Thursday, June 16 the stock rating was initiated by Bernstein with “Outperform”. The stock of Aetna Inc. (NYSE:AET) has “Buy” rating given on Monday, May 15 by Cantor Fitzgerald. The firm earned “Market Perform” rating on Friday, October 27 by BMO Capital Markets.
More recent Aetna Inc. (NYSE:AET) news were published by: Streetinsider.com which released: “Aetna (AET) Trump Proposal Unlikely To Impact Managed Care – Cantor Fitzgerald” on May 14, 2018. Also Benzinga.com published the news titled: “Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside” on May 03, 2018. Streetinsider.com‘s news article titled: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” with publication date: May 15, 2018 was also an interesting one.
Investors sentiment decreased to 0.83 in Q4 2017. Its down 0.08, from 0.91 in 2017Q3. It turned negative, as 69 investors sold AET shares while 345 reduced holdings. 147 funds opened positions while 198 raised stakes. 275.71 million shares or 1.91% less from 281.08 million shares in 2017Q3 were reported. Fjarde Ap reported 92,677 shares. Bridgeway Mngmt has 68,200 shares for 0.13% of their portfolio. Livforsakringsbolaget Skandia Omsesidigt reported 32,496 shares. Silvercrest Asset Lc owns 0.17% invested in Aetna Inc. (NYSE:AET) for 103,541 shares. Fincl Advisers Ltd Co holds 41,162 shares. Lowe Brockenbrough & holds 55,854 shares. Train Babcock Advsrs Lc reported 3,550 shares or 0.28% of all its holdings. Mufg Americas Corp owns 27,990 shares. Central Commercial Bank Trust Company invested in 0.45% or 10,366 shares. Tocqueville Asset Management Lp has invested 0.01% in Aetna Inc. (NYSE:AET). The New York-based Chesapeake Asset Mngmt Ltd Liability has invested 0.25% in Aetna Inc. (NYSE:AET). Advisors Asset Mgmt invested in 16,649 shares or 0.05% of the stock. Creative Planning stated it has 19,748 shares or 0.02% of all its holdings. Cornerstone Capital Liability Company stated it has 69,319 shares. Leisure Mngmt reported 1,225 shares or 0.18% of all its holdings.
Reilly Financial Advisors Llc increased Bb&T Corp (NYSE:BBT) stake by 176,136 shares to 177,218 valued at $8.81 million in 2017Q4. It also upped Spdr Series Trust stake by 22,977 shares and now owns 23,077 shares. Schwab Strategic Tr (SCHG) was raised too.
Among 26 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 10 Hold. Therefore 54% are positive. bluebird bio had 96 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Thursday, January 25 by Leerink Swann. The company was maintained on Friday, June 2 by Maxim Group. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Sell” rating given on Friday, October 14 by Cantor Fitzgerald. The rating was maintained by Cowen & Co on Tuesday, June 6 with “Buy”. The rating was maintained by Morgan Stanley on Monday, February 26 with “Equal-Weight”. Maxim Group maintained the stock with “Buy” rating in Tuesday, January 5 report. The stock has “Buy” rating by Jefferies on Monday, December 7. The rating was maintained by BTIG Research with “Hold” on Thursday, August 3. On Saturday, August 22 the stock rating was maintained by JP Morgan with “Overweight”. The rating was maintained by BTIG Research on Wednesday, May 31 with “Buy”.
More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Seekingalpha.com which released: “bluebird bio: Gene Therapy Best In Class” on May 16, 2018, also Streetinsider.com with their article: “bluebird bio (BLUE) to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti …” published on May 16, 2018, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.” on May 12, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Seekingalpha.com and their article: “Genomic Medicine: Catch The Gene Therapy Wave” published on May 14, 2018 as well as Globenewswire.com‘s news article titled: “Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive …” with publication date: May 15, 2018.